Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RELENZA

« Back to Dashboard

Relenza is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug.

The generic ingredient in RELENZA is zanamivir. Three suppliers are listed for this compound. Additional details are available on the zanamivir profile page.

Summary for Tradename: RELENZA

Suppliers: see list3

Pharmacology for Tradename: RELENZA

Clinical Trials for: RELENZA

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
Status: Recruiting Condition: Influenza, Human

A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects
Status: Withdrawn Condition: Healthy Subjects

Prophylactic Efficacy of Relenza Against Influenza A and B
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive; Bronchospasm; Influenza, Human; Asthma; Respiratory Disease; Exacerbation of COPD; Bronchitis; Otitis Maedia; Pneumonia; Sinusitis

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
Status: Completed Condition: Influenza, Human

Relenza® Sentinel Site Monitoring Program in Japan
Status: Completed Condition: Influenza, Human

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
Status: Recruiting Condition: Influenza, Human

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Status: Completed Condition: Influenza, Human

Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Status: Completed Condition: Influenza

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
Status: Terminated Condition: Gastric Influenza

Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
Status: Completed Condition: Influenza

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
POWDER;INHALATION021036Jul 26, 1999RXYes5,360,817<disabled>YY<disabled>
POWDER;INHALATION021036Jul 26, 1999RXYes5,648,379<disabled><disabled>
POWDER;INHALATION021036Jul 26, 1999RXYes6,294,572<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:
Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn